Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026

Lexaria Bioscience ( (LEXX) ) just unveiled an update.

Lexaria reported that its Phase 1b, 12‑week chronic study GLP-1-H24-4 in Australia met its primary endpoint, with all four DehydraTECH-based treatment arms deemed safe and well tolerated compared with the oral GLP-1 drug Rybelsus. Notably, the DehydraTECH-semaglutide formulation achieved a 47.9% reduction in total adverse events and a statistically significant 54.9% reduction in gastrointestinal adverse events versus Rybelsus, with all DehydraTECH arms showing marked decreases in nausea, vomiting and diarrhea, underscoring the platform’s potential to improve the side-effect profile of oral GLP-1 therapies. The company also highlighted that recent gross financings of US$7.5 million, following a period of limited cash resources, now provide funding runway through calendar 2026 for additional DehydraTECH research and partnering initiatives, potentially strengthening Lexaria’s position in the competitive metabolic and diabetes treatment landscape and supporting future development and commercialization opportunities.

The most recent analyst rating on (LEXX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a drug delivery technology company that develops and licenses its proprietary DehydraTECH platform to improve the delivery, performance and tolerability of active pharmaceutical ingredients, including GLP-1 drugs and cannabinoids. The company targets global pharmaceutical and therapeutics markets where enhanced oral formulations can offer competitive advantages in efficacy, safety and patient adherence.

Average Trading Volume: 646,331

Technical Sentiment Signal: Sell

Current Market Cap: $14.5M

For an in-depth examination of LEXX stock, go to TipRanks’ Overview page.